Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Metabolic · Dosing reference

Survodutide dosage

Doses given in registered human trials, how long they ran, and the arithmetic for working with vials.

InvestigationalAHuman trial evidenceTrial doses
Full research pageCycle-length evidenceComparePrefer Amiravo on Google
Regulatory status
Investigational
Human amounts
Phase 2: 0.6–6.0 mg once weekly (46–48 weeks); phase 3 SYNCHRONIZE: 3.6 mg or 6.0 mg once weekly (3.6 or 4.8 mg in SYNCHRONIZE-CN)
Route studied
Subcutaneous injection
Frequency
Once weekly (one phase 1 cohort received 2.4 mg twice weekly)
Half-life
A numerical human half-life was not located in the abstracts reviewed
Evidence grade
Grade A · Human trial evidence
Vial sizes on the market
6 mg · 10 mg
Other forms seen
—

What Survodutide is

Survodutide (BI 456906) is an investigational once-weekly peptide that activates both the glucagon and GLP-1 receptors. It has been studied in phase 2 and phase 3 randomized trials in obesity, type 2 diabetes and fatty liver disease. It is not an approved medicine, and this entry is for research information only.

Survodutide is described as a potent, acylated peptide that activates both the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R); a C18 fatty acid is attached as a half-life extending feature intended for once-weekly dosing in humans 6. Receptor pharmacology In cell-based assays, functional agonism of both receptors was characterised, and in mice the compound produced larger body-weight reductions than a… How it works →

Key evidence

  • le Roux et al., N Engl J Med (SYNCHRONIZE-1) · 2026 · Humans (726 adults with obesity and no diabetes (registry enrolment; 725 randomized and analysed in the publication))
    Mean body-weight change by the treatment-regimen estimand was -12.2% (3.6 mg), -13.0% (6.0 mg) and -5.4% (placebo); at least 5% weight reduction occurred in 72.6%, 71.9% and 46.3%, respectively 1. 1
  • Wharton et al., N Engl J Med (SYNCHRONIZE-2) · 2026 · Humans (755 adults with type 2 diabetes and BMI of 27 or more (registry enrolment; 752 randomized and analysed in the publication))
    Mean body-weight change was -8.2% (3.6 mg), -9.8% (6.0 mg) and -3.9% (placebo); mean HbA1c change from a baseline of 7.4% was -0.9, -0.8 and -0.2 percentage points 2. 2
  • Kaplan et al., Nat Med (SYNCHRONIZE-MASLD) · 2026 · Humans (216 adults with obesity and at-risk MASLD)
    A 30% or greater reduction in MRI-PDFF liver fat was reported in 84.2% versus 24.3% (efficacy estimand) and 68.5% versus 28.6% (treatment-regimen estimand) 3. 3
All studies on the research page

Schedules by time period

study arms from registered trials, laid out week by week. Each bar is what the label states or what investigators gave participants; none is a recommendation.

Registered trial

Phase 2 obesity trial (NCT04667377): study arms 17,5

Adults 18-75 years with BMI 27 or higher, without diabetes (387 enrolled) · 46 weeks

0.6 mg
SC · once weekly
Week-by-week table
PeriodAmount
Weeks 0–20.3 mg
Weeks 2–200.6 mg
Weeks 20–460.6 mg (maintenance)
2.4 mg
SC · once weekly
Week-by-week table
PeriodAmount
Weeks 0–20.3 mg
Weeks 2–40.6 mg
Weeks 4–60.9 mg
Weeks 6–101.2 mg
Weeks 10–141.8 mg
Weeks 14–202.4 mg
Weeks 20–462.4 mg (maintenance)
3.6 mg
SC · once weekly
Week-by-week table
PeriodAmount
Weeks 0–20.3 mg
Weeks 2–40.6 mg
Weeks 4–60.9 mg
Weeks 6–101.2 mg
Weeks 10–121.8 mg
Weeks 12–142.4 mg
Weeks 14–163.0 mg
Weeks 16–203.6 mg
Weeks 20–463.6 mg (maintenance)
4.8 mg
SC · once weekly
Week-by-week table
PeriodAmount
Weeks 0–20.3 mg
Weeks 2–40.6 mg
Weeks 4–60.9 mg
Weeks 6–81.2 mg
Weeks 8–101.8 mg
Weeks 10–122.4 mg
Weeks 12–143.3 mg
Weeks 14–164.2 mg
Weeks 16–204.8 mg
Weeks 20–464.8 mg (maintenance)

Weeks 1-20 were the dose-escalation phase (fixed escalation weeks 1-10, flexible escalation weeks 11-20, when participants with gastrointestinal adverse events could have their dose adjusted); weeks 21-46 were maintenance. A placebo arm received matched injections for 46 weeks.

Registered trial

Phase 2 type 2 diabetes trial (NCT04153929): study arms 18,19

Adults with type 2 diabetes on metformin with insufficient glycemic control (413 randomized) · 16 weeks

0.3 mg once weekly
SC · once weekly
Week-by-week table
PeriodAmount
Weeks 0–160.3 mg (maintenance)
0.9 mg once weekly
SC · once weekly
Week-by-week table
PeriodAmount
Weeks 0–20.3 mg
Weeks 2–40.6 mg
Weeks 4–160.9 mg (maintenance)
1.8 mg once weekly
SC · once weekly
Week-by-week table
PeriodAmount
Weeks 0–10.3 mg
Weeks 1–20.6 mg
Weeks 2–30.9 mg
Weeks 3–41.2 mg
Weeks 4–51.5 mg
Weeks 5–161.8 mg (maintenance)
2.7 mg once weekly
SC · once weekly
Week-by-week table
PeriodAmount
Weeks 0–20.6 mg
Weeks 2–41.2 mg
Weeks 4–51.8 mg
Weeks 5–62.4 mg
Weeks 6–162.7 mg (maintenance)
1.2 mg twice weekly (2.4 mg per week)
SC · twice weekly
Week-by-week table
PeriodAmount
Weeks 0–20.3 mg
Weeks 2–40.6 mg
Weeks 4–60.9 mg
Weeks 6–161.2 mg (maintenance)

Amounts are per injection; the registry gives total weekly amounts of 0.6, 1.2, 1.8 and 2.4 mg.

1.8 mg twice weekly (3.6 mg per week)
SC · twice weekly
Week-by-week table
PeriodAmount
Weeks 0–10.3 mg
Weeks 1–20.6 mg
Weeks 2–30.9 mg
Weeks 3–41.2 mg
Weeks 4–61.5 mg
Weeks 6–161.8 mg (maintenance)

Amounts are per injection; the registry gives total weekly amounts of 0.6, 1.2, 1.8, 2.4, 3 and 3.6 mg.

Comparator arms: placebo, and open-label semaglutide 0.25 mg (weeks 1-4), 0.5 mg (weeks 5-8), 1.0 mg (weeks 9-16) once weekly.

Registered trial

Phase 3 SYNCHRONIZE-1 (NCT06066515): study arms 1

Adults with BMI 30 or higher, or 27 or higher with at least one obesity-related complication, without diabetes (725 randomized) · 76 weeks

3.6 mg
SC · once weekly
  • 3.6 mg · Maintenance (start not reported)

Escalation steps not reported in the cited source.

6.0 mg
SC · once weekly
  • 6.0 mg · Maintenance (start not reported)

Escalation steps not reported in the cited source.

Once-weekly subcutaneous survodutide "at a dose adjusted up to 3.6 mg or 6.0 mg" or placebo; primary endpoints at week 76. Escalation steps not reported in the cited source.

Registered trial

Phase 3 SYNCHRONIZE-2 (NCT06066528): study arms 2

Adults with type 2 diabetes and BMI 27 or higher (752 participants) · 76 weeks

3.6 mg
SC · once weekly
  • 3.6 mg · Maintenance (start not reported)

Escalation steps not reported in the cited source.

6.0 mg
SC · once weekly
  • 6.0 mg · Maintenance (start not reported)

Escalation steps not reported in the cited source.

Once-weekly subcutaneous survodutide or placebo; primary endpoints at week 76. Escalation steps not reported in the cited source.

Registered trial

Phase 3 SYNCHRONIZE-MASLD: study arms 3

Adults with obesity (BMI 30 or higher, or 27 or higher with a metabolic complication) and at-risk MASLD · 48 weeks

6.0 mg
SC · once weekly
Week-by-week table
PeriodAmount
Weeks 24–486.0 mg (maintenance)

Weeks 0-24 were a dose-escalation period for uptitration to 6.0 mg; intermediate escalation steps not reported in the cited source. Dose reduction was permitted, with 2.4 mg the lowest allowed maintenance dose.

Randomized 2:1 to survodutide 6.0 mg (maintenance dose) or placebo once weekly for 48 weeks, with an optional 4-week extended treatment period at the assigned dose (full text, PMC).

Doses given in human trials

  • In SYNCHRONIZE-1 (NCT06066515), adults with obesity and no diabetes were randomized 1:1:1 to once-weekly subcutaneous survodutide with the dose adjusted up to 3.6 mg or 6.0 mg, or placebo, alongside lifestyle counselling, with primary assessment at week 76 1,9.
  • In SYNCHRONIZE-2 (NCT06066528), adults with type 2 diabetes and a BMI of 27 or more were randomized 1:1:1 to once-weekly subcutaneous survodutide at 3.6 mg or 6.0 mg, or placebo, with primary assessment at week 76 2,10.
  • In SYNCHRONIZE-MASLD, 216 adults were randomized 2:1 to once-weekly subcutaneous survodutide 6.0 mg (n = 146) or placebo (n = 70) for 48 weeks 3.
  • In the phase 2 obesity trial, participants were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide 0.6, 2.4, 3.6 or 4.8 mg or placebo for 46 weeks, comprising 20 weeks of dose escalation and 26 weeks of dose maintenance 5.
  • In the phase 2 MASH trial, participants were randomized 1:1:1:1 to once-weekly subcutaneous survodutide 2.4, 4.8 or 6.0 mg or placebo for 48 weeks, with a 24-week rapid dose-escalation phase followed by a 24-week maintenance phase 4.
  • SYNCHRONIZE-1 randomized 725 participants: 241 to survodutide 3.6 mg, 242 to 6.0 mg and 242 to placebo 1.
  • SYNCHRONIZE-2 randomized 752 participants: 250 to survodutide 3.6 mg, 251 to 6.0 mg and 251 to placebo 2.
  • SYNCHRONIZE-JP (NCT06176365) randomized 274 Japanese adults with obesity disease 1:1:1 to once-weekly survodutide 3.6 mg or 6.0 mg or placebo for 76 weeks 14.
  • SYNCHRONIZE-CN (NCT06214741) randomized 306 Chinese adults with overweight or obesity 1:1:1 to once-weekly subcutaneous survodutide 3.6 mg or 4.8 mg or placebo in a 76-week trial with primary endpoints at week 52 15.
  • The SYNCHRONIZE-CVOT registry record (NCT06077864) lists survodutide 3.6 mg, survodutide 6.0 mg and placebo arms, 5,531 participants enrolled and a composite cardiovascular primary endpoint assessed up to week 114 16.
  • In a phase 1 study in 36 healthy Japanese men with overweight or obesity, multiple rising doses were escalated over 16 weeks to maximum doses of 1.8 mg once weekly, 4.8 mg once weekly or 2.4 mg twice weekly (n=9 per dose group and placebo) 7.
  • In an open-label phase 1 trial in cirrhosis, participants with Child-Pugh A, B or C cirrhosis and matched healthy individuals received a single subcutaneous 0.3 mg dose (n=41); people with overweight or obesity with or without cirrhosis (Child-Pugh A or B) then received once-weekly doses escalated from 0.3 mg to 6.0 mg over 24 weeks and maintained for 4 weeks (n=41) 8.
  • In the phase 2 obesity trial, 386 participants were treated (0.6 mg n=77, 2.4 mg n=78, 3.6 mg n=77, 4.8 mg n=77, placebo n=77) 5; in the phase 2 MASH trial, 293 randomized participants received at least one dose 4.

How long did human studies run?

  • Phase 2 obesity: 46 weeks (20-week escalation, 26-week maintenance) 5. Phase 2 MASH: 48 weeks (24-week escalation, 24-week maintenance) 4. Phase 1 cirrhosis multiple-dose cohorts: 28 weeks 8. Japanese phase 1: 16 weeks 7.
  • SYNCHRONIZE-1 and SYNCHRONIZE-2: primary assessment at week 76 1,2; SYNCHRONIZE-MASLD: 48 weeks 3; SYNCHRONIZE-JP: 76 weeks 14; SYNCHRONIZE-CN: 76 weeks with primary endpoints at week 52 15.
Cycle-length evidence for Survodutide

Who was excluded from the studies

  • SYNCHRONIZE-1 registry exclusion criteria include a self-reported body-weight change of more than 5% within 3 months, any obesity medication within 3 months, HbA1c of 6.5% or higher, a history of type 1 or type 2 diabetes, NYHA class IV heart failure, clinically significant gastric emptying abnormality, chronic or acute pancreatitis or lipase/amylase above 2× ULN, and a personal or family history of medullary thyroid carcinoma or MEN 2 9.
  • The phase 2 obesity trial enrolled adults aged 18–75 years with BMI of 27 or higher and without diabetes 5.

Side effects reported in studies

  • Gastrointestinal adverse events (any)
    80.9% (3.6 mg) and 89.7% (6.0 mg) versus 47.9% placebo · SYNCHRONIZE-1, adults with obesity 1
  • Gastrointestinal adverse events (any)
    72.8% (3.6 mg) and 77.7% (6.0 mg) versus 38.6% placebo · SYNCHRONIZE-2, adults with type 2 diabetes and obesity 2
  • Nausea
    66% survodutide versus 23% placebo (pooled survodutide arms) · Phase 2 MASH trial, adults with biopsy-confirmed MASH 4
  • Diarrhea
    49% versus 23% placebo · Phase 2 MASH trial 4
  • Vomiting
    41% versus 4% placebo · Phase 2 MASH trial 4
  • Serious adverse events
    8% survodutide versus 7% placebo · Phase 2 MASH trial 4
  • Any adverse event / gastrointestinal adverse event
    91% and 75% with survodutide versus 75% and 42% with placebo · Phase 2 obesity dose-finding trial, 46 weeks 5
Full adverse-event data

Survodutide draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength
sizes on the market
2 · Water added
3 · Amount per draw
4 · Syringe
Your mix
10 mg + 2 mL water = 5 mg/mL
10 units holds 0.5 mg (500 mcg)
Draw toEnter an amount in step 3
0102030405060708090100
U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Watermg/mLDraw
0.5 mL20—
1 mL10—
1.5 mL6.667—
2 mL5—
2.5 mL4—
3 mL3.333—
5 mL2—

Supplies and handling

  • Lyophilized vial
    Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
  • Sterile diluent
    The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
  • Graduated syringes
    Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
  • Alcohol prep pads
    For wiping vial stoppers before each puncture.
  • Nitrile gloves
    Clean gloves for aseptic handling.
  • Sharps container
    Puncture-resistant container for used needles.
Step-by-step reconstitution guideStorage and transport accessories

Storage

Storage conditions for research peptides vary with the supplied form; follow the supplier's documentation and certificate of analysis. Lyophilized peptides are generally sensitive to heat, light and moisture.

  • Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
  • Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
  • Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent
The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed
Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles
Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution
This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed
Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status
Investigational. The phase 3 reports published in 2026 describe survodutide as an investigational agent 1,2, and no Drugs@FDA application record was returned for it when the database was queried on 22 October 2026 12.
United States (FDA)
Survodutide is investigational; an openFDA query of Drugs@FDA application data on 22 October 2026 returned no application record for it 12, and the 2026 phase 3 publications describe it as an investigational agent 1,2.
Sport (WADA)
Survodutide is not named among the S2.2 growth hormone and related-peptide examples in the 2026 Prohibited List text reviewed; the full list was not screened line by line for this entry, so athletes should consult WADA directly 11.

Status varies by country and changes over time. How we describe regulatory status.

Survodutide compared with related compounds

CompoundStatusEvidenceHuman amountsHalf-life
SurvodutideInvestigationalATrial dosesA numerical human half-life was not loca
SemaglutideFDA-approvedAFDA labelApproximately 1 week; present in the cir
TesofensineInvestigationalBTrial dosesAbout 234 hours (M1 metabolite about 374
MazdutideApproved outside the USATrial doses150.9 to 403.5 hours (phase 1b in overwe
CagrilintideInvestigationalATrial doses159 to 195 hours (phase 1b, co-administe
SLU-PP-332Not approved — research use onlyCNone establishedUnknown in humans

Frequently asked questions

What doses of Survodutide have been studied in humans?
Survodutide is investigational. This page lists the amounts given in each cited trial as facts about those studies.
Is there an established Survodutide cycle length?
No cycle length or break has been established. Human studies administered Survodutide for the periods listed on this page; those are study durations, not a recommended course.
How much bacteriostatic water should be added to a Survodutide vial?
There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.
How many units is a given amount on an insulin syringe?
On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.
What is the half-life of Survodutide?
A numerical human half-life was not located in the abstracts reviewed
Is Survodutide FDA-approved?
Investigational. Investigational. The phase 3 reports published in 2026 describe survodutide as an investigational agent 1,2, and no Drugs@FDA application record was returned for it when the database was queried on 22 October 2026 12.

References

  1. Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1) N Engl J Med. 2026
  2. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes (SYNCHRONIZE-2) N Engl J Med. 2026
  3. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Nat Med. 2026
  4. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis N Engl J Med. 2024
  5. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial Lancet Diabetes Endocrinol. 2024
  6. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy Mol Metab. 2022
  7. A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906 in healthy Japanese men with overweight/obesity Diabetes Obes Metab. 2023
  8. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/GLP-1 receptor dual agonist, in cirrhosis J Hepatol. 2024
  9. SYNCHRONIZE-1 registration record (NCT06066515) ClinicalTrials.gov. 2023
  10. SYNCHRONIZE-2 registration record (NCT06066528) ClinicalTrials.gov. 2023
  11. World Anti-Doping Agency International Standard Prohibited List 2026 WADA. 2026
  12. Drugs@FDA application data queried through openFDA for survodutide (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  13. PubChem compound records for survodutide PubChem. 2026
  14. Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial Diabetes Obes Metab. 2026
  15. Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE-CN) Diabetes Ther. 2026
  16. A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE-CVOT, NCT06077864) ClinicalTrials.gov. 2026
  17. A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight (registry results: participant flow group descriptions) ClinicalTrials.gov. 2023
  18. A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes (registry results: participant flow group descriptions) ClinicalTrials.gov. 2022
  19. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Diabetologia. 2024

Last reviewed October 23, 2026 by the Amiravo editorial team. Editorial policy · Report an error